- Merck (NYSE:MRK) awarded an ~$1.21B firm-fixed-price contract for 1,696,629 treatment courses of the oral antiviral MK-4482.
- Work will be performed in Kenilworth, New Jersey, with an estimated completion date of June 15, 2022.
- Fiscal 2020 Coronavirus Aid, Relief and Economic Security (or CARES) Act funds in the amount of ~$1.21B were obligated at the time of the award.
- Previously: Merck inks supply deal with U.S. government for molnupiravir in COVID-19 (June 9)
Merck nabs ~$1.21B U.S. Army contract for treatment courses of the oral antiviral
Recommended For You
About MRK Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| MRK | - | - |
| Merck & Co., Inc. | ||